Advances in the treatment of psychiatric disorders in long-term care homes.
Study Goal
The researchers aimed to evaluate the effectiveness of melatonin in managing behavioral symptoms of dementia in older adults in long-term care settings.
Results Summary
The study found negative results regarding melatonin's efficacy in managing behavioral symptoms of dementia, indicating it did not demonstrate significant benefits in this context.
Population
Older adults in long-term care homes with behavioral symptoms of dementia.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
psychosocial interventions | decrease | behavioral symptoms | older adults in long-term care (LTC) homes | - | some evidence to support the use | #1 |
sensory interventions such as aromatherapy and calming music | decrease | behavioral symptoms | older adults in long-term care (LTC) homes | - | some evidence to support the use | #2 |
behavioral management techniques | decrease | behavioral symptoms | older adults in long-term care (LTC) homes | - | some evidence to support the use | #3 |
cognitive stimulation | decrease | behavioral symptoms | older adults in long-term care (LTC) homes | - | some evidence to support the use | #4 |
physical activity | decrease | behavioral symptoms | older adults in long-term care (LTC) homes | - | some evidence to support the use | #5 |
staff training | decrease | behavioral symptoms | older adults in long-term care (LTC) homes | - | some evidence to support the use | #6 |
psychotherapies such as reminiscence therapy and cognitive behavior therapy | decrease | depression | older adults in long-term care (LTC) homes | - | some evidence to support the use | #7 |
antipsychotic aripiprazole | neutral | behavioral symptoms of dementia | older adults in long-term care (LTC) homes | - | studies of | #8 |
prazosin | neutral | behavioral symptoms of dementia | older adults in long-term care (LTC) homes | - | studies of | #9 |
medication-discontinuation | neutral | behavioral symptoms of dementia | older adults in long-term care (LTC) homes | - | trials | #10 |
melatonin | no change | behavioral symptoms of dementia | older adults in long-term care (LTC) homes | - | negative studies involving | #11 |
oxcarbazepine | no change | behavioral symptoms of dementia | older adults in long-term care (LTC) homes | - | negative studies involving | #12 |
psychosocial interventions | decrease | behavioral symptoms associated with dementia | older adults in long-term care (LTC) homes | small or moderate | may confer significant benefits | #13 |
PURPOSE OF REVIEW: Psychiatric disorders are common among older adults in long-term care (LTC) homes and the LTC population is rapidly growing in many countries. Treatment of psychiatric conditions in this population is challenging given the psychosocial environment and physical frailty of the population. This review highlights some important advances in pharmacological and nonpharmacological interventions in this setting. RECENT FINDINGS: There is some evidence to support the use of psychosocial interventions for behavioral symptoms, including those utilizing sensory interventions such as aromatherapy and calming music; behavioral management techniques; cognitive stimulation; physical activity; and staff training. There is also some evidence to support the use of psychotherapies such as reminiscence therapy and cognitive behavior therapy for depression. Recent literature on the pharmacological management of behavioral symptoms of dementia have included studies of the antipsychotic aripiprazole, prazosin, and medication-discontinuation trials along with two negative studies involving melatonin and oxcarbazepine. SUMMARY: The literature on psychosocial interventions for behavioral symptoms associated with dementia has been criticized for lack of vigor, but there is growing evidence from studies with improved methodology that these interventions may confer significant benefits, although the effect sizes are often small or moderate. More well designed trials of pharmacological therapies in the LTC population are also necessary.